Viralytics Limited

Cancer vaccines have gained in prominence over the last couple of decades, as the emergence of immuno-oncology has validated the immune system’s essential role in maintaining healthy cell division. Th

Oncorus Inc. has closed a $79.5m series B round to initiate the first clinical trial for its herpes simplex-based oncolytic virus technology platform and select the first product candidate for its ot

Transgene SA has downplayed the significance of the Phase III failure of oncolytic virus Pexa-Vec, noting the differences between the out-licensed asset and the rest of its pipeline. On 2 August, Tra

AstraZeneca PLC and immunotherapy specialist Transgene SA are to work together to develop armed oncolytic vaccinia virus candidates. The companies announced on 2 May that they have signed a deal to